By Ilana Greene and Jonathan Ephraim
Back in the ‘old days’, a doctor would usually assess a patient, ascertain the medical condition, and prescribe medication that is specifically suited to that patient. A compounding pharmacist would then come up with the patient’s prescribed medicine. While it’s good that the medication is customized to the particular needs of the patient, compounded medications do take time to create. This is why medication started to become mass-produced, alongside America’s industrialization around the 1950’s. By 1960’s, mass produced medication became the norm and compounded medication became the thing of the past.
These days, sales of automated drugs bring in billions and billions of dollars for pharmaceutical companies all over the world. Most of us are dependent on these mass-produced medicines for our well-being. Unfortunately, these medicines do not provide the solution for everyone, as there are people who suffer from conditions beyond the scope of mass-produced medicine. As a result, the practice of compounding medication is making a strong comeback. The only problem is that these drugs have yet to receive FDA support or regulation.
This is where Imprimis Pharmaceuticals plays an important role. Imprimis aims to answer the need for customized medication.
At present, Imprimis Pharmaceuticals is revolutionizing compounded medications with their products having FDA approval. A growing number of people need their medicine customized since studies have shown that some mass-produced products have harmful effects on patients when taken for long periods.
Take for example NSAIDs (non-steroidal anti-inflammatory drugs) such as Motrin, Aleve, and Advil. Common side effects of these drugs are nausea, vomiting, stomach pain, and stomach bleeding. Chief of Rheumatology Robert Hoffman, M.D., of the Miller School of Medicine at the University of Miami said, "Gastritis, esophageal reflux disease [heartburn or GERD], and bleeding ulcers are all problems that can develop from NSAIDs.”
Patients who develop these ulcers would have to stop taking these NSAIDs altogether and will need additional medication to address the side effects and avoid further complications.
Since Imprimis concentrates on specialized medication, the company aims for the improvement of compounded drugs and their quality. Imprimis is commercially developing compounded medication to meet the approval of the FDA and make them available to the people who need these drugs. The company’s revolutionary technology of drug delivery through topical cream preparations makes sure that treatment is exact and specific. This includes a certain drug that will enter Phase 3 by the latter part of 2013. The drug is already a part of America’s presently growing market for topical NSAIDs and its qualities show that it will be the leading drug in its field. Imprimis’ technology will definitely change how medication, particularly analgesics, will be administered to and accessed by patients.
Imprimis Pharmaceuticals strives to be a pioneer when it comes to meeting patients’ needs. It aims to provide products that are still unmet and not yet available anywhere else, working closely with the Professional Compounding Centers of America. The company’s primary goal is to make available customized compounded medication that is safe and easy to access. Imprimis CEO Mark Baum said, “These are drug formulations that are typically sold by… compounded pharmacies all over the country. Imprimus is taking them through a traditional regulated FDA process in order to bring them to the market.”
With the extensive PCCA catalog to aid the company’s endeavors, Baum is certain of Imprimis’ success. He adds, “The company has created a relationship with the largest player in the compounding pharmacy industry in North America. The PCCA has over 10,000 proprietary compounded drug formulations and… more than a dozen proprietary drug delivery technologies.”
Imprimis, with its exclusive partnership with PCCA, will advance and make the 10,000 drug formulations in the PCCA’s library marketable and more accessible to the public. This library is Imprimis’ source of formulations that will change the pharmaceutical market drastically, by way of internal development or development partnership. With the help of PCCA’s library, Imprimis can potentially develop drug formulations for the mass market on a yearly basis. This is also very cost effective since Imprimis will use the research provided by the PCCA.
Baum explains, “This will enable the delivery of drugs intravenously… as well as through the mouth, through the nose, and trans-vaginally, which gives us the ability… to affect men’s health, women’s health, as well as gastrointestinal conditions.” The PCCA will be in charge of the development of these specialized medications while Imprimis will take care of the marketing and promotion. Consumers will also be assured of these drugs’ safety and effectiveness since PCCA patients have tried and tested them. The result will be safer and more improved products for people.
Imprimis is backed by a very strong and determined group of people with the will to succeed. With their management team, processes are made easy and transactions conducted smoothly. Imprimis strives to create productive and lasting partnerships with leading health care providers and with its ever growing number of products, ensure that its customer base will increase and grow stronger. With Imprimis, people are assured of high quality, safe, and personalized care.
Filed under: Uncategorized